Recombinant adeno-associated (AAV) viruses have unique properties, which make them ideal vectors for gene transfer targeting the myocardium. Numerous serotypes of AAV have been identified with variable tropisms towards cardiac tissue. In the present study, we investigated the time course of expression of eight different AAV serotypes in rat myocardium and the nature of the immunity against these serotypes. We first assessed whether neutralizing antibodies (NAb) were present for any of the serotype in the rats. We injected 100 ml of each AAV 1-8 serotype (10 12 DNAse resistant particles/ml), encoding LacZ gene, into the apical wall of rat myocardium. At 1, 4, 12 and 24 weeks after gene delivery, the animals were killed and b-galactosidase (b-gal) activity was assessed by luminometry. Additionally, LacZ genomic copies and AAV capsids copies were measured through standard polymerase chain reaction analysis and cryosections from the area of viral injection were stained for X-gal detection at the same time points. No NAbs were detected against any of AAV serotypes. At all the time points studied, AAV1, 6 and 8 demonstrated the highest efficiency in transducing rat hearts in vivo. Parallel to the results with b-gal activity, the highest levels LacZ and AAV DNA genomic copies were with AAV1, 6 and 8. The positive X-gal staining depicted by these serotypes confirmed these results. These results indicate that among the various AAV serotypes, AAV1, 6 and 8 have differential tropism for the heart unaffected by pre-existing NAb in the rat. Although AAV 1 and 6 vectors induced rapid and robust expression and reach a plateau at 4 weeks, AAV 8 continued increasing until the end of the study. AAV 2, 5 and 7 vectors were slower to induce expression of the reporter gene, but did reach levels of expression comparable to AAV1 and AAV6 vectors after 3 months. Gene Therapy (2007) 14, 989-997.
Introduction
Cardiovascular diseases and specifically congestive heart failure (CHF) remain a leading cause of morbidity and mortality around the world. Over the last few years, a number of molecular abnormalities have been described in the pathogenesis of CHF. These cellular and molecular abnormalities are all potential targets for gene modifications. For this reason, gene therapy has been considered as an alternative and novel experimental therapeutic approach to target the various underlying mechanisms responsible for the decreased contractility in the failing heart. The feasibility of in vivo cardiac gene transfer by viral vectors has been consistently demonstrated over the last few years. In addition, in short-term experiments, gene transfer studies targeting calcium-handling proteins such as SERCA2a 1,2 and phospholamban 3 have proven that this approach can improve cardiac function. For CHF applications, the requirements for a gene transfer vector include non-pathogenicity, sustained transgene expression throughout the myocardium and enhanced cardiac tropism. These desirable features for cardiac gene transfer seem to reside in the adenoassociated virus (AAV) vectors. For this reason, AAV derived technology has recently been identified as the most promising means to target myocardial contractile dysfunction.
AAVs belong to the viral family Parvoviridae (parvoviruses). AAV has a non-enveloped proteinaceous capsid with a diameter of approximately 20-25 nm 4 containing single-stranded DNA genome of approximately 4.7 kb encoding two genes. 5 One is the rep gene, which encodes for proteins involved in DNA replication. The other is the cap gene, which by differential splicing, encodes for three proteins that make up the protein coat of the virus. AAV is a dependovirus, so named because members of this group cannot replicate autonomously. AAV requires co-infection with a helper virus, such as herpesvirus or adenovirus, to provide necessary helper functions in trans to allow for AAV replication. 6 AAV vectors have eliminated all the viral genes. This adds a safety feature that not only prevents the generation of replicationcompetent pseudo wild-type AAV via homologous recombination, 7 but also mitigates the possibility of immune reactions caused by undesired viral gene expression, 8, 9 a significant problem seen with other viral vector systems. 10 The general lack of immune response against the vector-transduced cells as well as the efficient and persistent gene transfer has set AAV vectors apart from other gene delivery systems, especially to muscle tissues. Moreover, its small particle size facilitates diffusion in muscle and extracellular matrices. All these properties of AAV have been identified by current human gene therapy trials. [11] [12] [13] New AAV serotypes are continuously being identified. At present, over 100 AAV variants have been isolated. [14] [15] [16] [17] [18] Until recently, the majority of targeting cardiac muscle were conducted using AAV-based vectors employed serotype 2. AAV2 carrying a pseudophosphorylated form of phospholamban, 19 the VEGF 20 or the human heme oxygenase 21 genes have all been used in animal models of heart disease to reverse cardiac dysfunction. However, it has become apparent that AAV2-based vectors are generally thought to be inefficient at transducing myocardial cells in vitro and in vivo, 22 and AAV2-vector-mediated gene transfer may be limited by prevalent neutralizing antibodies (NAbs) in humans due to prior exposure to wild-type virus. 23 Whereas different AAV serotypes have differential tropism to various tissues in the body, available data are usually difficult to interpret due to heterogeneity in the vectors doses and titers, promoters, transgenes, species and methodology used, the effectiveness of different serotypes in transducing genes in cardiac muscle has not been explored in detail until now.
The overall purpose of this study was to carefully examine the expression patterns and time course of expressions for eight different serotypes of AAV injected into the myocardium. In addition, our results will hopefully guide the judicious use of each serotype of AAV in the setting of cardiac gene transfer and ultimately clinical use of these vectors.
Results

Dose-response to AAV2
To identify the optimal dose of the AAV vectors, we injected rat hearts with AAV2.LacZ at doses ranging from 10 8 to 10 13 drp/ml and then evaluated enzyme activity 1 month after the injection. The choice of 10 12 drp/ml AAV vector dose was based on this doseresponse curve as shown in Figure 1 . Three to four hearts were used for each concentration. Beyond 10 12 drp/ml, there was no further increase in the enzyme activity; accordingly, this dose was chosen in order to ensure a high-quality b-galactosidase (b-gal) expression during the study.
b-Gal activity, AAV genome capsids and X-gal staining
To assess whether the b-gal activity of rat myocardium AAV infected could be influence by preexisting NAb, sera were collected from the rats before infection and assayed for in vitro anti-AAV1 to eight neutralizing activity. No NAbs were detected against any of AAV serotypes. The lack of NAb at the start of the study ensured that the parameters observed at the time points established are not influenced by prior NAb activity. After 1 week (Figure 2 ) of gene transfer into the myocardium with AAV1-8, the levels of b-gal activity increased significantly for AAV1, 6, 7 and 8. b-Gal activity from AAV2 and 3 were not detectable. The increase in the enzymatic activity depicted by AAV8 was evidently higher than the others serotypes, although did not attain statistical difference compared with AAV1, 6 and 7. The AAV DNA copies followed the same pattern as the b-gal activity; however, as a technique with higher specificity and sensitivity, the difference between AAV8 and the others AAV was statistically higher. Histochemical sections showed X-gal staining for AAV1, 6, 7 and 8 at this time point. Four weeks (Figure 3 ) after gene delivery, the levels of b-gal activity from AAV1, 5, 6, 7 and 8 continued increasing proportionally. Although b-gal activity from AAV2 became evident, the enzymatic activity from AAV3 continued to be undetectable, as well as the expression of AAV4. At this time point, the difference in the b-gal activity from AAV8 and the rest of the serotypes was more marked. The AAV genome capsids continued to follow the b-gal activity profile. Nevertheless, values reached by AAV6 were comparable to the ones reached by AAV8. As was expectable, at this time point the histochemical reaction for X-gal was positive for all the samples except for AAV3 and 4. At week 12 ( Figure 4 ) after AAV injection, all the AAV serotypes showed significant b-gal activity respect to the control values, however, AAV8 break out from the rest. At the AAV DNA capsids level, the outline was the same. X-gal staining was positive for all serotypes except for the AAV3, accordingly to the lowest values of b-gal activity and AAV copies attained by this vector. Twentyfour weeks ( Figure 5 ) after the gene transfer, the b-gal activity profile was similar to the previous time point. AAV3 was below the detectable level and AAV4, although measurable, did not reach significant enzymatic activity respect to the control values. AAV8 was once more the vector with more transduction at the protein level. The AAV DNA copies pattern did not differ from the one described by b-gal activity. At this time point, the X-gal histochemistry was positive for all serotypes except for AAV3. The statistical difference 13 drp/ml). The data were normalized for the protein concentration and subtracted from those collected from uninjected animals. The figure shows that AAV2 elicited a dose-dependent increase in the b-gal activity in the rat heart. At the 10 12 drp/ml the enzyme activity reached a plateau. Data are means7s.e.m. *Po0.05 vs the previous value. Table 2 for the AAV DNA copies.
LacZ DNA copies
To further corroborate the data showed above, we also measured at each time point the LacZ genomic copies given for each AAV. Table 1 shows the values obtained by standard polymerase chain reaction (PCR) analysis. At each time point, the values in LacZ DNA copies were associated with the corresponding value in b-gal activity and in AAV capsids copies. Supplementary Table 3 shows the statistical difference among the serotypes at the time points studied.
Time course efficiency of different AAV
For better comparison, b-gal activity of the different AAV serotypes time course is depicted in Figure 6 . AAV1, 6, 7 and 8 induced a rapid and robust expression detectable as soon as 1 week post-injection. After 4 weeks of gene delivery, b-gal activity reached significant values respect to control for almost all serotypes. AAV1, 2, 5, 6, and 7 achieved their maximal expression 12 weeks after the gene transfer, as there was not further increase in b-gal activity after this time point. For AAV serotypes 2, 5 and 7, the time course of b-gal activity was parallel to the time course for AAV1 and 6 ( Figure 6 ) and the levels of b-gal activity at 12 weeks after injection were close to the levels achieved by AAV1 and 6 ( Figure 4a ). However, after 12 weeks, there was a decline in b-gal activity associated with AAV2 and 5 (Figures 4a and 6 ). AAV3 and 4 only attained significant b-gal activity increase 12 weeks after the injection and this expression was temporary. AAV8 showed persistent increasing b-gal activity over the period of the study. The expression levels of this serotype were much higher than the others at all the time points studied.
Discussion
Achieving efficient and long-lasting levels of gene transfer throughout the myocardium has proven a major challenge to genetic manipulation of cardiac muscle function. This strategy holds great potential for the treatment of numerous cardiovascular diseases, including CHF. In this report, we have demonstrated the efficiency of eight AAV serotypes in transducing rat myocardium in vivo during a 6-month period. AAVmediated gene expression has been demonstrated for the life of treated rats, and at the longest time points studied reach until 4 years. 24 This is the first study, to our knowledge, which investigates the time course expression of eight different serotypes, in the same experi- 25 Serotype 6 shares 499% amino acid homology with serotype 1 and was generated by a recombination between AAV1 and 2 14, 26, 27 and both AAV1 and 6 have shown to transduce skeletal muscle more efficiently than AAV2. 28, 29 Indeed, these similarities between serotypes 1 and 6 could be the explanation for the parallel pattern followed throughout the study ( Figure 6 ). Additionally, these two AAV vectors reached their b-gal activity plateau at 4 weeks post-injection ( Figure 6 ) and maintained this high expression level during the length of the study. The dynamic behavior of these AAV vectors is particularly interesting, as they rapidly achieved a strong gene expression, slightly increasing between 3 and 6 months, avoiding substantial fluctuations. These features ensure a fast and maintained gene expression. Du et al.,
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who performed a similar study comparing AAV1-5 in a 1-year period, also found that serotype 1 was the AAV that most efficiently transduce cardiac muscle in mice, with the same intramyocardial injection technique. In this study, they compared green fluorescence protein (GFP) expressing cardiomyocytes from mice and in contrast with our results, they did not find levels of GFP expressing cells from AAV5 comparable to AAV1 at any of the time points examined. An interesting observation from this study is that both AAV1 and 2 had different dynamics with respect to our results. The highest GFP expression was reached at 1-month postinjection and after this time point the expression was declining. We have shown stable expression of these vectors during 6 months. This discrepancy could account on the different techniques used to assess the degree of the gene expression (GFP expressing cells vs b-gal activity) and the specie utilized (mice vs rats). In another elegant work, Wang et al., 31 compared the gene expression among several AAV serotypes including AAV1 and 6 which, and accordingly with our results, showed a strong cardiac gene expression given by these serotypes two months after gene delivery by intraperitoneal injection in neonatal mice.
Novels AAV serotypes have emerged recently isolated from nonhuman primates. Including among these are AAV7 and 8 serotypes. 15 Our results showed that AAV8 was much more effective in transduce cardiac tissue compared with serotypes 1-7 at all the time points studied. Notably, the frame time of this study was not enough for AAV8 to reach a steady state expression. Further investigation is required to evaluate the longterm effect of AAV8 beyond 6 months, as an exaggerated and uncontrolled effect is not desirable as therapeutic strategy. These serotypes were also compared against AAV1, 2, 5, and 6 in neonatal mice by Wang et al. 31 Consistently with our study, they showed the highest myocardium protein expression conferred by AAV8 in a 2 months range time. Accordingly, Louboutin et al. The LacZ genomic copies from AAV serotypes 1-8 presented the following relative values: for 1 week time point, AAV84AAV64AAV14 AAV74AAV24AAV44AAV54AAV3; for 4 weeks time point, AAV84AAV64AAV14AAV74AAV54AAV24AAV44AAV3; for 12 weeks time point, AAV84AAV64AAV14AAV5XAAV74AAV2XAAV44AAV3; and for the 24 weeks time point, AAV84AAV64AAV14 AAV74AAV24AAV54AAV44AAV3. These relative relationship among the serotypes were similar to the one obtained by enzymatic activity and by the AAV DNA capsids at each time point. Overall results of b-gal activity indicating the time course followed by each AAV serotype. AAV8 was clearly the serotype that reaches the quickest and highest value during the time frame of the study. AAV1 and 6 developed a significant b-gal activity as soon as 1 week after the gene transfer, and maintain this high performance during 6 months. AAV2, 5 and 7 achieved b-gal activity values comparable to AAV1 and 6 at 12 weeks post-injection, however, at the last time point the enzymatic activity decreased. AAV3 and 4 only attained significant b-gal activity increase 12 weeks after the gene delivery. Values from Figures 2-5 were placed here for visual comparison.
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Cardiac gene transfer by different AAV serotypes J Palomeque et al observed similar high gene transduction levels with AAV1, 7 and 8 in skeletal muscle. An interesting observation provided by the X-gal staining is the distribution of AAV7 and 8 within the myocardium. While AAV1, 2, 4, 5 and 6 showed clear tropism for the endocardium (Du et al. 30 and Kawamoto et al. 33 and our results) AAV7 and 8 have shown expression preference for the epicardium. Accordingly, the epicardium expression given by AAV8 can also be observed in mice after tail vein injection of the vector (Wang et al.
31 Figure 3b ). This pattern of expression was maintained throughout the four time points of our study, leading to serotypes 7 and 8 an attractive utility to modify specific functions into different regions within the heart. It is well known that difference in action potential duration (APD) between endo and epi myocytes rely on ion currents. 34, 35 Previous investigations have demonstrated differences in expression of K + currents, which are thought to underlie regional, 36 transmural 37 and disease-induced changes in APD. 38 The electrophysiological changes that occur in response to myocardial failure result in the prolongation of APD and enhancement of APD heterogeneity, 38, 39 which constitutes the substrate for reentrant excitation, malignant ventricular arrhythmias and sudden death. 39 Regional changes in the K + currents components (cKv4.3, cKv1.4 and cKChIP2 for I to ; cERG for I Kr ; cKvLQT1 and cMinK for I Ks ; and cKir2.1 for I K1 ) could be achieved by gene transfer through vectors that selectively transduce different myocardial layers, likely AAV7 or 8 for the epicardium, to evoke an electrophysiological remodeling in the failing heart. The results presented herein add to the AAV7 and 8 characterization the complete comparison with the rest of the AAV available until present in a wide range of time, in the same specie and under identical methodology applied to verify the AAV expression.
AAV2, 5 and 7 followed the same pattern in terms of expression level and time course. The fact that AAV5 transfection efficiency was comparable to AAV2 and 7 was unexpected to us. Neither Du et al., 30 26, 40, 41 the present study is the first one to show a significant and increasing levels of gene expression into the myocardium after AAV5 delivery. It is possible that platelet-derived growth factor, which have been suggested as putative receptor for AAV5 cellular transduction, 42 among other factors plays a significant role in the transduction profile in the myocardium.
The time course gene expression described by AAV4 and 3 was poor during the entire of the study. AAV4 has been suggested to infect primarily ependymal cells when introduced into the mouse brain 40 and the in vivo receptor for AAV3 is at present unknown. AAV4 shares with AAV5 the same cell-mediated transduction pathway, which require sialic acid but differ in sialic acid linkage specificity. 43 Furthermore, our results are in agreement with those from Du et al., 30 who showed no significant gene expression delivered by AAV3 and 4, neither in vitro in mice and human cardiomyocytes nor in vivo in mice hearts.
AAV-mediated gene expression can be potentially obstructed by a host's immune response to its component proteins. Several reports have demonstrated the failure to generate further transduction expression by AAV readministration correlated with the presence of virus-NAb developed in response to a previous exposure to the virus. [44] [45] [46] [47] As 80% of human samples were positive for anti-AAV antibodies to AAV2 and 30-70% of the samples were positive for the presence of NAbs, 23, 48 the preexisting nature immunity in rodents without deliberately immunization has been less studied. The fact that in the present study, the NAbs did not reach significant levels before the gene delivery, supports the notion that the b-gal expression elicited by the different AAV serotypes was unaffected by preexisting immunity. However, the animals may have developed humoral immunity able to modify the gene expression induced by the different AAV serotypes after the transfection. Nevertheless, this fact seems unlikely, at least, during the period of the study given that the b-gal activity levels remain constants once a plateau was reached.
Among the several items discussed above, the different time course depicted by AAV1, 6 and 8 clearly highlighted the preferable tropism of these serotypes between the others for the cardiac muscle. Receptor type and number, surface charge and hydrophobicity, affinity for extracellular matrix, propensity to get into the nuclease, to uncoat, to become ubiquitinated and degrade, are some of features that could probably play a role in the different gene expression developed by the serotypes 1-8 observed throughout the period studied.
Efforts to understand the role of tropism of AAV serotypes are timely and necessary, in order to be able to capitalize on future therapeutic possibilities. In summary, we have shown in the present study the gene expression in cardiac muscle on a wide time frame developed by eight different AAV serotypes. Our outcome suggests that AAV1, 6 and 8 are the more appropriate vectors for gene delivery into the myocardium. However, further longitudinal studies are necessary to evaluate the extent of AAV8 gene expression. These results will allow for an optimal choice of delivery reagent for specific gene therapy applications, specifically for the treatment of chronic cardiac muscle diseases. Additional experiments in large animals as well as less invasive and more effective techniques to deliver these vectors need to be performed to confirm our results in rat.
Materials and methods
Vectors
Vector production, harvest, purification and testing were carried out as previously described. 49 The specific AAV vector serotypes used in this study contain each AAV serotype 1, 2, 3, 4, 5, 6, 7, and 8 viral capsid and a singlestranded DNA containing the LacZ gene cDNA driven by a CMV immediate-early promoter/enhancer, a hybrid intron, and a bovine growth hormone poly-adenylation 
Animals and vector injection
Housing and handling of the rats were in compliance with the National Institutes of Health and institutional guidelines and approved by the Institutional Animal Care and Use Committee of the Massachusetts General Hospital. Three-month-old male Sprague-Dawley rats were purchased from Charles River laboratories. To test the capacity of AAV serotypes for efficient myocardial transduction, we used eight different vectors to infect cardiac muscle. Briefly, the animals were anesthetized with 60 mg/kg pentobarbital intraperitoneally, intubated, and ventilated (SAR-830; CWE, Ardmore, PA, USA). Each different AAV serotype was injected into the left ventricular apex through a thoracotomy, in separate experiments. We injected a total of 10 12 DNAse resistant particles/ml (drp/ml) of AAV serotypes 1-8, each in 100 ml phosphate-buffered saline (PBS), with a 29-gauge needle. The chest incision was then closed, the artificial ventilation was removed and the rats were transferred back to their cages. The animals were killed at 1, 4, 12 and 24 weeks after gene transfer. A total of eight hearts were used per vector at each time point, using identical numbers of drp/ml. Three hearts injected with PBS were used as controls. The non-virus control group data were used to normalize the values obtained from the AAVinjected hearts.
b-Gal activity
After killing, the heart of each animal was rapidly excised, the apex was cut (E150 mg piece) and flash frozen in liquid nitrogen. The frozen myocardium were then powdered using a mortar and pestle and the protein was extracted with a protease-inhibiting buffer containing 50 mM Tris-HCl, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid and 1X Complete protease inhibitor (Roche, Indianapolis, IN, USA). The extract was then measured for protein concentration via spectrophotometric absorption with the Bradford reagent (Bio-Rad laboratories, Hercules, CA, USA). Protein samples averaged 5.9670.12 mg/ml. The extract was analyzed for b-gal activity with a commercial luminometry kit from BD Biosciences (San Diego, CA, USA) according to the product manual; activity was read on a luminometer. Endogenous b-gal activity was inactivated by incubation at 481C for 50 min. All protein concentration and b-gal activity assays were averaged over a triplicate reading and represent n ¼ 4 individual hearts. The b-gal activity was expressed as relative light units (RLU) and was normalized for the protein concentration and subtracted from those collected from uninjected animals.
X-gal staining
An individual heart from each AAV at each time point was rapidly excised after killing, embedded in TBS medium (Triangle Biomedical Sciences, Durham, NC, USA) and frozen in alcohol dry-ice cooled. Transverse cryostat 8-10-mm sections were fixed for 10 min in cold 0.5% glutaraldehyde, rinsed with PBS two times at room temperature and reacted at 371C over-night in X-gal mixer containing mM MgCl 2 , 0.01% Na-deoxycholate, 0.02% NP-40, 5 mM ethyleneglycol tetraacetate (EGTA), 5 mM K 3 Fe(CN) 6 and 5 mM K 4 Fe(CN) 6 Á 3H 2 O supplemented with 1 mg/ml X-gal (Fisher Scientific, Pittsburgh, PA, USA). After staining, tissues were rinsed in 0.5 mM EGTA, dried and covered with aqueous mounting medium (Biomeda, Foster City, CA, USA) and glass coverslips to preserve the samples.
Polymerase chain reaction
A TaqMan qPCR assay was developed to detect and quantify specific sequences for AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7 and AAV8 along with LacZ, qPCR amplification and fluorescence detection was performed using the ABI PRISM 7700 Sequence detection system. Three replicate qPCR reactions were performed on each specimen's DNA using the oligonucleotide primers and fluorescent probes. Each qPCR plate was run with one set of standards, a naïve rat genomic DNA (negative control) and the qPCR reagent control. These controls were used to monitor the potential for nonspecific amplifications of rat genomic DNA, contamination of qPCR reagents and contamination of specimen DNA during the extraction process. For each qPCR run, the sequence detector software created a standard curve by plotting the mean CT value (the cycle at which the reporter signal can be detected above baseline fluorescence) of each standard vs LogN starting copy number assigned to each standard. The software then performed a linear regression analysis to calculate the number of copies of the target sequence in each reaction. The mean copy number of the duplicate reactions for each specimen was calculated.
We used the following oligos of the various AAV serotypes to run the PCR assays: serotypes in sera were analyzed using a rodent-based enzyme-linked immunosorbent assay assay for detection of antibodies against AAV1, 2, 3, 4, 5, 6, 7 and 8. Assays were performed in a 96-well format using AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7 and AAV8 vectors. Plates were read on CytoFluor Fluorescence Plate Reader (PerCeptive Biosystems, Applied Biosystems, Foster City, CA, USA), using CytoFluor software. An increased titer of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7 and AAV8 NAbs was determined by measuring the inhibition of infectivity. Inhibition of infectivity is exhibited as a reduction in fluorescence levels. For each plate in this assay, the average raw fluorescence and CV of the vector control and the background control were calculated. The average Background Control value was deducted from the average Vector Control value, which results in the 'Background-Adjusted-Fluorescence of the Vector Control'. The 'Background-Adjusted-Fluorescence of the Vector Control' is then divided by 2, and the result is designed as the 'Titer Determining Value' for that plate. For each plate in this assay, the 'Fold Above Background' was calculated by dividing the 'Background-AdjustedFluorescence of the Vector Control' by the average raw fluorescence of the Background Control. The average raw fluorescence was calculated for each dilution of positive control and test specimen. The average raw fluorescence of the Background Control for that plate was then deducted, which results in the 'Background-AdjustedFluorescence' for that test or control specimen dilution. The titer of each test specimen or positive control is designated as the highest dilution of that specimen or control that has a 'Background-Adjusted-Fluorescence' value less than the 'Titer Determining Value' for that plate. For a valid assay: at the highest dilution of the positive control there had to be a fluorescence level within 2-fold of the 'Background-Adjusted-Fluorescence of the Vector Control', and at the lowest dilution of the positive control the fluorescence level must be within 2-fold of the average raw fluorescence of the Background Control. These demonstrate that the appropriate dilution series of the positive control was run. For a valid plate, the 'Fold Above Background' value must be 45, and the average raw fluorescence of the Background Control should be o1000. For a valid test sample, there had to be an average raw fluorescence level within 2-fold of the 'Background-Adjusted-Fluorescence of the Vector Control' at the greatest dilution of test specimen to demonstrate that the appropriate range of dilutions in run.
Statistics
Comparisons within groups were assessed by TukeyKramer multiple comparisons test. A value of Po0.05 was taken to indicate statistical significance.
